에 대한 최신 뉴스 Quantum BioPharma (NASDAQ:QNTM) 주식

Quantum BioPharma

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma Ltd

News

Guidance

BYRN

Byrna Says Well-Positioned To Generate Additional Cash And Expand Profitability In 2025 And Beyond

<p>Needham  analyst Quinn Bolton   maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $85 to $60.</p>


Price Target

Analyst Ratings

MCHP

Needham Maintains Buy on Microchip Technology, Lowers Price Target to $60

Byrna Expects Strong YoY Growth As It Continues Executing Strategic Initiatives, While Q1 Historically Experiences Seasonal Slowdown In Consumer Spending

<p>Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.10 by 310 percent.&nbsp;</p>


Earnings

Earnings Beats

Earnings Misses

Byrna Technologies Q4 2024 GAAP EPS $0.41 Beats $0.10 Estimate

<p>Northland Capital Markets  analyst Greg Gibas   maintains A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) with a Market Perform and lowers the price target from $40 to $36.</p>


AMRK

Northland Capital Markets Maintains Market Perform on A-Mark Precious Metals, Lowers Price Target to $36

ENFY

Enlightify Enters Cooperation Agreement With Huadian Gaintime Investment Fund Management Co. To Jointly Develop And Invest In Renewable Energy Projects

<p>Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent.  The company reported quarterly sales of $1.002 billion which beat the analyst consensus estimate of $984.071 million by 1.82 percent.  This is a 12.46 percent increase over sales of $891.000 million the same period last year.</p>


ULCC

Frontier Group Holdings Q4 2024 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.002B Beat $984.071M Estimate

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $50 price target.</p>


Reiteration

PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $50 Price Target

<p> Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Registered Direct Offering") at a purchase price of $1.00 per share. </p>


Penny Stocks

Offerings

Palatin Technologies Announces $4.7M Direct Offering Of 4.688M Shares Of Common Stock At A Price Of $1.00 Each

<p><i>Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio</i><br /><br />&nbsp;</p>
<p>NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4YyVFRqflcXwGqhUPTu2VjFDGgtLwrW5VTXaIRFyk-IIIPuNlzUJ1jQBS1XGZkeW2u04U49EFMJDxbmDv53lI7G3RQd22H4wFDcieWxEMMdgqIbb8q9NPbI8fnx3Mbk4">Conduit Pharmaceuticals Inc. </a>(Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=ZTbTPPHxjU9RAGWKZNAxD9OEmTHgwAmSW93ya-3jDGJAoT_s17QSwtV023t8itckPH1PGyypdAhJgLcMBCOkJaQcs-63P0X8YmDPgL0iXJx3xZdGfHDatM_nKDvGX7dz7Ku1_yv2_IHuKXXf6ohNgLeoc5JQt7gupWXvm-x_9eb7n5iuRdTxyAAS0XEs3neoudqFzXxh_jB7kprIFCx9LQ4deVpkjll0AX-SQ0a7U-aMQzK0jJ0jkiPTYYdvTnPy">CDT)</a> ("<strong>Conduit</strong>" or the "<strong>Company</strong>"), today announces the successful completion of all milestones in Phase I of its strategic collaboration with Sarborg Limited. This transition to Phase II marks a positive step forward in Conduit's strategy to explore the integration advanced artificial intelligence (AI) and cybernetics into its drug development processes. With Phase I now complete, the Company is pleased to transition to Phase II, which will focus on the creation of personalized software dashboards to enhance operational efficiency and reporting.</p>
<p>The focus of Phase I was to establish a strong foundation for the collaboration with Sarborg, identify key inputs for the algorithmic approach, and align Sarborg's services with Conduit's strategic goals. The collaboration, initiated in December 2024, aims to revolutionize drug development by leveraging cutting-edge AI technologies to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Phase I included teach-in sessions with management, the validation of Conduit's proprietary inputs that are critical for Sarborg's cybernetic models and, thirdly, a comprehensive market analysis of cocrystal candidates.</p>
<p>Conduit and Sarborg worked closely to align AI-driven processes with Conduit's portfolio needs, ensuring that proprietary inputs were tailored to maximize the potential of key assets, including AZD1656, AZD5904, AZD5658, CDT1656, and the AZD1656 cocrystals. Additionally, an in-depth market analysis of cocrystal candidates provided actionable insights into the competitive landscape, patent positioning, and market opportunities.</p>
<p>Conduit is now transitioning to Phase II, which is expected to focus on building the technological infrastructure necessary to support AI-driven drug development of its current and future portfolio of products. A key deliverable of this phase will be the creation of personalized software dashboards, designed to provide Conduit's key personnel with real-time access to critical data related to clinical trials, drug discovery, and portfolio management. These dashboards are designed to enable more agile and informed decision-making, allowing the Company to remain focused on delivering impactful clinical trials in autoimmune disorders.</p>


Conduit Pharmaceuticals Transitions To Phase II In Sarborg Collaboration For AI-Driven Drug Development; Phase II To Focus On Personalized Software Dashboards To Enhance Efficiency And Decision-Making

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Market Perform and raises the price target from $60 to $70.</p>


LITE

Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Raises Price Target to $70

GAN Announces Extension Of End Date Of SEGA SAMMY Merger Agreement From Feb. 7 To May 31

<p>Rosenblatt  analyst Barton Crockett   maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and raises the price target from $46 to $51.</p>


PINS

Rosenblatt Maintains Buy on Pinterest, Raises Price Target to $51

FTEL

Fitell Announces $10M Registered Direct Offering Of 1,992,032 Shares And Warrants At $5.02 Each, Closing Expected By February 10, 2025

<p>4 analysts have expressed a variety of opinions on Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.0, with a high estimate of $22.00 and a low estimate of $16.00. Surpassing the previous average price target of $19.50, the current average has increased by 2.56%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738933330_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Extreme Networks. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Extreme Networks. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Extreme Networks compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Extreme Networks's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Extreme Networks's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Extreme Networks analyst ratings.</strong></a></p>
<h2>Get to Know Extreme Networks Better</h2>
<p>Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.</p>
<h3>Extreme Networks's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Extreme Networks's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-5.74%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Extreme Networks's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>2.64%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Extreme Networks's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>17.59%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Extreme Networks's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.69%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>4.52</strong>, Extreme Networks faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EXTR

Deep Dive Into Extreme Networks Stock: Analyst Perspectives (4 Ratings)

Biotech

General

MAZE

Maze Therapeutics Doses The First Patient In Its Phase 2 HORIZON Clinical Trial Of MZE829 As Potential Treatment For APOL1 Kidney Disease

<p>AMETEK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) today announced its Board of Directors has approved an 11% increase in its quarterly cash dividend on common stock to $0.31 per share from $0.28 per share. The dividend is payable on March 31, 2025, to shareholders of record as of March 14, 2025. This dividend increase will raise the indicated annual rate to $1.24 per share.</p>
<p>Additionally, AMETEK's Board of Directors approved a $1.25 billion share repurchase authorization. This new authorization replaces the previous $1 billion share repurchase authorization approved in May 2022, of which approximately $590 million remained available.</p>


Dividends

Buybacks

AMETEK Increases Quarterly Dividend From $0.28 To $0.31 and Announces $1.25B Share Repurchase Authorization,  Replaceing The Previous $1B Share Repurchase Authorization Approved In May 2022, Of Which ~$590M Remained Available

<p>Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Selective Insurance Gr, revealing an average target of $100.25, a high estimate of $116.00, and a low estimate of $87.00. This current average represents a 7.46% decrease from the previous average price target of $108.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738933285_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Selective Insurance Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$93.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$87.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Selective Insurance Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Selective Insurance Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Selective Insurance Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Selective Insurance Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SIGI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Selective Insurance Gr analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Selective Insurance Gr</h2>
<p>Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. Since 1977, Selective has focused its sales efforts on small businesses, offering commercial products that include workers' compensation, general liability, property, and auto insurance. Selective also has a small personal insurance segment (under 20% of total premiums), selling auto and homeowner's coverage.</p>
<h3>Financial Insights: Selective Insurance Gr</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Selective Insurance Gr showcased positive performance, achieving a revenue growth rate of <strong>0.96%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Selective Insurance Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>7.42%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Selective Insurance Gr's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.17%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Selective Insurance Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.69%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.17</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SIGI

The Analyst Verdict: Selective Insurance Gr In The Eyes Of 4 Experts

<p>Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Air Products &amp; Chemicals and provided 12-month price targets. The average target is $357.5, accompanied by a high estimate of $385.00 and a low estimate of $320.00. Observing a 5.01% increase, the current average has risen from the previous average price target of $340.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738933270_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Air Products &amp; Chemicals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$375.00</td>
<td>-</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$365.00</td>
<td>$345.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Air Products &amp; Chemicals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Air Products &amp; Chemicals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Air Products &amp; Chemicals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Air Products &amp; Chemicals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Air Products &amp; Chemicals analyst ratings.</strong></a></p>
<h2>About Air Products &amp; Chemicals</h2>
<p>Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $12.1 billion in revenue in fiscal 2024.</p>
<h3>Breaking Down Air Products &amp; Chemicals's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Challenges:</strong> Air Products &amp; Chemicals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-0.12%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Air Products &amp; Chemicals's net margin is impressive, surpassing industry averages. With a net margin of <strong>61.17%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Air Products &amp; Chemicals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>12.13%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Air Products &amp; Chemicals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.09%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.88</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


8 Analysts Have This To Say About Air Products & Chemicals

<p>Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) reported quarterly sales of $27.98 million which missed the analyst consensus estimate of $28.00 million by 0.08 percent.  This is a 78.89 percent increase over sales of $15.64 million the same period last year.</p>


Byrna Technologies Q4 Sales $27.98M Miss $28.00M Estimate

Quantum Biopharma ( ($TSE:QNTM) ) just unveiled an announcement. Quantum BioPharma Ltd. has announced its dual listing on Upstream, a global securi...

Quantum BioPharma Expands Global Reach with Upstream Listing

Quantum BioPharma (QNTM) will be back in the Ontario Superior Court of Justice on January 24, 2025. Quantum BioPharma is seeking a Court Order decl...

Quantum BioPharma to be in court with Raza Bokhari on January 24

Quantum Biopharma ( ($TSE:QNTM) ) just unveiled an announcement. Quantum BioPharma is involved in ongoing legal proceedings against Dr. Raza Bokhar...

Quantum BioPharma Advances Legal Actions Against Former CEO

Quantum Biopharma ( ($TSE:QNTM) ) just unveiled an update. Quantum BioPharma Ltd., a company listed on NASDAQ, CSE, and FRA, has announced the clos...

Quantum BioPharma Closes Third Tranche Offering with Amended Terms

New option listings for January 21st include GOLDMAN SACHS PHYSICAL GOLD ETF (AAAU), SWAN HEDGED EQUITY US LARGE CAP ETF (HEGD), ETFS Physical Pall...

Five new option listings and  option delistings on January 21st

Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary sup...

Quantum Group announces results from unbuzzd trial

The latest announcement is out from Quantum Biopharma ( ($TSE:QNTM) ). On February 4, 2025, Quantum BioPharma announced the successful results of a...

Quantum BioPharma's unbuzzd™ Shows Promising Results in Clinical Trial

Quantum Biopharma ( ($TSE:QNTM) ) has shared an announcement. On February 6, 2025, Quantum BioPharma announced that its licensee, Celly Nutrition, ...

Quantum BioPharma's Licensee Celly Nutrition Plans IPO After Positive Trial Results

09:52 EST QNTM Stock trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>...

QNTM Stock trading resumes

09:42 EST QNTM Stock trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking...

QNTM Stock trading halted, volatility trading pause

APDN

BBIG

BIVI

BSGM

CLNN

DZSI

EBET

FENG

GAME

GYRE

ISPO

LFLY

PALL

PFIS

PRTG

QNTM

RBOT

SRNE

TCRT

Press Releases

Quantum Biopharma Announces Closing of First Tranche

Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Quantum Biopharma Announces Closing of Second Tranche

Quantum Biopharma Ltd. Approved to Dual List on Upstream

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

IPOs

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study

Comments

Quantum BioPharma

뉴스

에 대한 최신 뉴스 Quantum BioPharma (NASDAQ:QNTM) 주식

뉴스

파트너 / 기고자

벤징가 글로벌